Gilbert Nyamuswa
Hematology & Oncology · Henderson, NVNPI 1235136854
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.7%), gifts and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Novartis at 55.5% of the total. Reporting peaked in 2019 at $2,285 and has fallen 89.2% since, to $247 in 2021. That places this record below the midpoint for hematology & oncology clinicians in NV, where the typical reported total is $9,657.
Across 129 payments — averaging $31.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Incyte Corporation$202
- Eisai Inc.$129
- Mallinckrodt Enterprises LLC$117
- Astellas Pharma US Inc$110
- Gilead$101
- plus $1K from 26 others
Across 6 payments — averaging $5041.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$13K
- Astrazeneca UK Limited$10K
- Immunomedics, Inc.$7K
- Onquality Pharmaceuticals (USA) LLC$2K
What the payments were for
- Food & beverage$2,12352%
- Education$170%
- Gifts$1,96548%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 37 | $2,277 |
| Incyte Corporation | 7 | $202 |
| Eisai Inc. | 6 | $129 |
| Mallinckrodt Enterprises LLC | 1 | $117 |
| Astellas Pharma US Inc | 6 | $110 |
| Gilead(2 entities) | 7 | $101 |
| Amgen | 4 | $98 |
| Genentech USA, Inc. | 5 | $85 |
| Secura Bio, Inc. | 5 | $79 |
| Pfizer | 4 | $73 |
| AstraZeneca | 4 | $69 |
| EMD Serono, Inc. | 5 | $67 |
| Array Biopharma Inc | 2 | $62 |
| Sanofi | 3 | $51 |
| Blueprint Medicines Corporation | 3 | $51 |
| Bristol Myers Squibb | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Johnson & Johnson | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Clovis Oncology, Inc. | 4 | $41 |
| Merck | 3 | $39 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $38 |
| Seagen Inc. | 2 | $37 |
| Bayer | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Janssen Scientific Affairs, LLC | 1 | $29 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Tesaro, Inc. | 1 | $21 |
| Acrotech Biopharma Inc. | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISQALI$1,182
- CELLEX/XTS PHOTOPHERESIS SYSTEM$117
How this compares
$4,106 in reported general payments places this provider in the 25th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Henderson
- Anthony NguyenHenderson$210K
- Russell GollardHenderson$105K
- Rupesh ParikhHenderson$67K
- Ramalingam RatnasabapathyHenderson$25K
- Stephani ChristensenHenderson$10K
- Resty TibayanHenderson$10K
- Nutan ParikhHenderson$10K
- Muhammad GhaniHenderson$9K
- Khoi DaoHenderson$8K
- Nicholas VogelzangLas Vegas$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.